Literature DB >> 22314929

Therapeutics in Huntington's Disease.

Annie Killoran1, Kevin M Biglan.   

Abstract

OPINION STATEMENT: There is no specific treatment for Huntington's disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient's professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD's complexity, it is best managed with a multidisciplinary approach that includes a movement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.

Entities:  

Year:  2012        PMID: 22314929     DOI: 10.1007/s11940-012-0165-x

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  36 in total

Review 1.  Role of tetrabenazine for Huntington's disease-associated chorea.

Authors:  Linda H Poon; Gail A Kang; Audrey J Lee
Journal:  Ann Pharmacother       Date:  2010-05-04       Impact factor: 3.154

2.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

Authors:  S M Hersch; S Gevorkian; K Marder; C Moskowitz; A Feigin; M Cox; P Como; C Zimmerman; M Lin; L Zhang; A M Ulug; M F Beal; W Matson; M Bogdanov; E Ebbel; A Zaleta; Y Kaneko; B Jenkins; N Hevelone; H Zhang; H Yu; D Schoenfeld; R Ferrante; H D Rosas
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

3.  Efficacy of levetiracetam in Huntington disease.

Authors:  Marina de Tommaso; Olimpia Di Fruscolo; Vittorio Sciruicchio; Nicola Specchio; Claudia Cormio; Maria Fara De Caro; Paolo Livrea
Journal:  Clin Neuropharmacol       Date:  2005 Nov-Dec       Impact factor: 1.592

4.  Bilateral human fetal striatal transplantation in Huntington's disease.

Authors:  R A Hauser; S Furtado; C R Cimino; H Delgado; S Eichler; S Schwartz; D Scott; G M Nauert; E Soety; V Sossi; D A Holt; P R Sanberg; A J Stoessl; T B Freeman
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

5.  Effect of donepezil on motor and cognitive function in Huntington disease.

Authors:  E Cubo; K M Shannon; D Tracy; J A Jaglin; B A Bernard; J Wuu; S E Leurgans
Journal:  Neurology       Date:  2006-10-10       Impact factor: 9.910

Review 6.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

7.  [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].

Authors:  S Giménez-Roldán; D Mateo
Journal:  Neurologia       Date:  1989-10       Impact factor: 3.109

8.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Authors:  Kevin Duff; Leigh J Beglinger; Margaret E O'Rourke; Peg Nopoulos; Henry L Paulson; Jane S Paulsen
Journal:  Ann Clin Psychiatry       Date:  2008 Jan-Mar       Impact factor: 1.567

9.  Paroxetine retards disease onset and progression in Huntingtin mutant mice.

Authors:  Wenzhen Duan; Zhihong Guo; Haiyang Jiang; Bruce Ladenheim; Xiangru Xu; Jean Lud Cadet; Mark P Mattson
Journal:  Ann Neurol       Date:  2004-04       Impact factor: 10.422

10.  Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Authors:  Carsten Saft; Thorsten Lauter; Peter H Kraus; Horst Przuntek; Juergen E Andrich
Journal:  BMC Neurol       Date:  2006-02-28       Impact factor: 2.474

View more
  3 in total

Review 1.  Progress in developing transgenic monkey model for Huntington's disease.

Authors:  Brooke R Snyder; Anthony W S Chan
Journal:  J Neural Transm (Vienna)       Date:  2017-11-10       Impact factor: 3.575

Review 2.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

3.  Speech and language therapy for management of chronic cough.

Authors:  Claire Slinger; Syed B Mehdi; Stephen J Milan; Steven Dodd; Jessica Matthews; Aashish Vyas; Paul A Marsden
Journal:  Cochrane Database Syst Rev       Date:  2019-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.